Gilead to stop late-stage study of Covid-19 treatment
Gilead to stop late-stage study of COVID-19 treatment
(Reuters) – Gilead Sciences Inc said on Monday it had decided to stop a late-stage trial of its intravenous treatment, Veklury, in high-risk non-hospitalized patients with COVID-19.
The company said it no longer believes that developing a multiple day injection that requires administration in a healthcare setting addresses an unmet need for non-hospitalized patients.
FILE PHOTO: Gilead Sciences Inc pharmaceutical company is seen after they announced a Phase 3 Trial of the investigational antiviral drug Remdesivir in patients with severe coronavirus disease (COVID-19), during the outbreak of the coronavirus disease (COVID-19), in Oceanside, California, U.S., April 29, 2020. REUTERS/Mike Blake/File Photo
The decision to stop the study is not due to efficacy or safety concerns, Gilead said.
Reporting by Dania Nadeem in Bengaluru; Editing by Anil D’Silva
Our Standards: The Thomson Reuters Trust Principles.
Reuters source:
